Literature DB >> 22162025

Gene expression profiling identifies mechanisms of protection to recurrent trinitrobenzene sulfonic acid colitis mediated by probiotics.

Rob Mariman1, Bas Kremer, Marjan van Erk, Tonny Lagerweij, Frits Koning, Lex Nagelkerken.   

Abstract

BACKGROUND: Host-microbiota interactions in the intestinal mucosa play a major role in intestinal immune homeostasis and control the threshold of local inflammation. The aim of this study was to evaluate the efficacy of probiotics in the recurrent trinitrobenzene sulfonic acid (TNBS)-induced colitis model and gain more insight into protective mechanisms.
METHODS: Moderate chronic inflammation of the colon was induced in BALB/c mice by repetitive intrarectal challenges with TNBS. Administration of probiotics started 2 weeks before colitis induction and was continued throughout colitis development.
RESULTS: Long-term administration of Lactobacillus plantarum NCIMB8826 or the probiotic mixture VSL#3 reduced intestinal inflammation induced by TNBS, evident from improved colon morphology and less influx of innate (CD11b(+) ) and adaptive (CD4(+) /CD8(+) ) immune cells in the intestinal mucosa and decreased proinflammatory serum cytokines (interferon-gamma [IFN-γ], interleukin [IL]-17, IL-1β, monocyte chemoattractant protein [MCP]-1) in probiotic-treated mice. Genomewide expression analysis of colonic tissues using microarrays revealed differences in expression of genes related to inflammation and immune processes between untreated and probiotic treated mice. Principal component analysis revealed that probiotic treatment resulted in a shift of gene expression profiles toward those of healthy controls. Effects of probiotics on colonic gene expression were most profound during active inflammation, in particular on gene clusters related to mast cells and antimicrobial peptides. The results were substantiated by suppression of chemokine gene expression.
CONCLUSIONS: Our data are in favor of a model in which probiotics downregulate expression of chemokines in the colon, thereby decreasing influx of inflammatory cells and rendering mice resistant to the induction of colitis.
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22162025     DOI: 10.1002/ibd.22849

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  15 in total

1.  Induction of murine TNBS colitis is strictly controlled by a modified method using continuous inhalation anesthesia with sevoflurane.

Authors:  Tomohiro Terai; Satoshi Osawa; Shinya Tani; Shinji Oishi; Yoshifumi Arai; Takanori Yamada; Mitsushige Sugimoto; Takahisa Furuta; Shigeru Kanaoka; Hiroaki Miyajima; Ken Sugimoto
Journal:  Dig Dis Sci       Date:  2014-01-23       Impact factor: 3.199

Review 2.  Animal models of inflammatory bowel disease: a review.

Authors:  Nidhi Goyal; Ajay Rana; Abhilasha Ahlawat; Krishna Reddy V Bijjem; Puneet Kumar
Journal:  Inflammopharmacology       Date:  2014-06-07       Impact factor: 4.473

Review 3.  Modulation of immunity and inflammatory gene expression in the gut, in inflammatory diseases of the gut and in the liver by probiotics.

Authors:  Julio Plaza-Diaz; Carolina Gomez-Llorente; Luis Fontana; Angel Gil
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

4.  The Probiotic VSL#3 Modulates Colonic Macrophages, Inflammation, and Microflora in Acute Trinitrobenzene Sulfonic Acid Colitis.

Authors:  Raymond A Isidro; Abdon Lopez; Myrella L Cruz; Mayra I Gonzalez Torres; Gladys Chompre; Angel A Isidro; Caroline B Appleyard
Journal:  J Histochem Cytochem       Date:  2017-07-10       Impact factor: 2.479

5.  Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis.

Authors:  Sander van der Marel; Anna Majowicz; Karin Kwikkers; Richard van Logtenstein; Anje A te Velde; Anne S De Groot; Sybren L Meijer; Sander J van Deventer; Harald Petry; Daniel W Hommes; Valerie Ferreira
Journal:  World J Gastroenterol       Date:  2012-08-28       Impact factor: 5.742

Review 6.  Nutritional modulators of ulcerative colitis: clinical efficacies and mechanistic view.

Authors:  Mi-Kyung Sung; Mi-Young Park
Journal:  World J Gastroenterol       Date:  2013-02-21       Impact factor: 5.742

Review 7.  Quality of methods reporting in animal models of colitis.

Authors:  Michael Bramhall; Oscar Flórez-Vargas; Robert Stevens; Andy Brass; Sheena Cruickshank
Journal:  Inflamm Bowel Dis       Date:  2015-06       Impact factor: 5.325

8.  The probiotic mixture VSL#3 dampens LPS-induced chemokine expression in human dendritic cells by inhibition of STAT-1 phosphorylation.

Authors:  Rob Mariman; Frans Tielen; Frits Koning; Lex Nagelkerken
Journal:  PLoS One       Date:  2014-12-29       Impact factor: 3.240

9.  Temporal colonic gene expression profiling in the recurrent colitis model identifies early and chronic inflammatory processes.

Authors:  Bas Kremer; Rob Mariman; Marjan van Erk; Tonny Lagerweij; Lex Nagelkerken
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

10.  Effects of increase in fish oil intake on intestinal eicosanoids and inflammation in a mouse model of colitis.

Authors:  Nabil Bosco; Viral Brahmbhatt; Manuel Oliveira; Francois-Pierre Martin; Pia Lichti; Frederic Raymond; Robert Mansourian; Sylviane Metairon; Cecil Pace-Asciak; Viktoria Bastic Schmid; Serge Rezzi; Dirk Haller; Jalil Benyacoub
Journal:  Lipids Health Dis       Date:  2013-05-31       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.